ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2021 Operating Results

Rhea-AI Summary

ImmunoGen Inc. (NASDAQ: IMGN) will host a conference call on October 29, 2021, at 8:00 a.m. ET to discuss its third quarter operating results and provide a business update. Investors can join the call by dialing (877) 621-5803 with conference ID 1587202, or access it via the company's website. ImmunoGen focuses on developing advanced antibody-drug conjugates (ADCs) aimed at improving cancer treatment outcomes. The company emphasizes its commitment to creating targeted therapies that enhance anti-tumor activity.

Positive

• Upcoming conference call to discuss third quarter results, which may provide insights into financial performance.
• Focus on developing next-generation antibody-drug conjugates targeting cancer.

Negative

• None.

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, October 29, 2021 to discuss its third quarter operating results. Management will also provide a brief update on the business.

CONFERENCE CALL INFORMATION
To access the live call by phone, dial (877) 621-5803; the conference ID is 1587202. The call may also be accessed through the Investors and Media section of the Company’s website, www.immunogen.com. Following the call, a replay will be available at the same location.

ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211014005008/en/

INVESTOR RELATIONS AND MEDIA

ImmunoGen

Courtney O'Konek

781-895-0600

courtney.okonek@immunogen.com

OR

FTI Consulting

Robert Stanislaro

212-850-5657

robert.stanislaro@fticonsulting.com

Source: ImmunoGen Inc.

FAQ

What time is ImmunoGen's conference call scheduled for?

The conference call is scheduled for 8:00 a.m. ET on October 29, 2021.

How can I access the ImmunoGen conference call?

You can access the call by dialing (877) 621-5803 with conference ID 1587202 or through the Investors and Media section of ImmunoGen's website.

What is ImmunoGen's focus in cancer treatment?

ImmunoGen is focused on developing advanced antibody-drug conjugates to improve outcomes for cancer patients.

What is the stock symbol for ImmunoGen?

The stock symbol for ImmunoGen is IMGN.